OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Real-time Boerse Frankfurt Warrants 07:44:14 17/06/2024 BST | ||
| 7.98 EUR | +2.57% |
|
| Current month | +22.71% | ||
| 1 month | +44.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 17/06/24 | 7.98 | +2.57% |
| 14/06/24 | 7.78 | -2.63% |
| 13/06/24 | 7.99 | +3.63% |
| 12/06/24 | 7.71 | +10.62% |
| 11/06/24 | 6.97 | +4.34% |
Real-time Boerse Frankfurt Warrants
Last update June 17, 2024 at 07:44 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW884Y |
| ISIN | DE000SW884Y0 |
| Date issued | 19/04/2024 |
| Strike | 2,424 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.86 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.21 € |
|---|---|
| Lowest since issue | 4.72 € |
| Spread | 0.3 € |
| Spread % | 3.62% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832
DKK
Average target price
2,464
DKK
Spread / Average Target
+34.46%
- Stock Market
- Certificates
- Certificat